Durham drug developer Scynexis announced Friday that it has named Marco Taglietti to be its new CEO effective April 1.
Taglietti will replace Yves Ribeill, who will remain the company’s president and a member of its Board of Directors.
Ribeill has led Scynexis for the past 15 years. Taglietti joined the company’s board in December. He previously served as executive vice president for research and development and chief medical officer of Forest Laboratories.
Scynexis also announced Friday that its chief medical officer, Carole Stable, is stepping down effective Feb. 20.
“I have tremendous faith in Marco's ability to lead Scynexis into the future and look forward to working closely with him as we continue to advance the development of our lead compound for the treatment of invasive fungal infections," Ribeill said in a statement. "I also want to thank Carole for her work in getting SCY-078 back into the clinic and wish her the best in her next endeavor."
Scynexis, which spun out of Aventis in 2000, does not have a drug on the market. It's developing SCY-078, a treatment for serious and life-threatening fungal infections.
The company raised $40 million from its IPO in early May after deducting fees and expenses and paying off a $15 million credit line.
In January, SCY-078 was granted fast track status by the Food and Drug Administration. The designation accelerates the review process for drugs that have the potential to offer significant improvement in treatment compared with products already on the market.